Physician profile
John A Piede
NPI 1972782548
$8,432.17
in general payments reported to CMS, 2019-2025
62 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,927 · 2020: $779 · 2021: $1,225 · 2022: $1,423 · 2023: $1,121 · 2024: $887 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,078.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,631.62 | 2019-2025 | |
| Janssen Biotech, INC. | $673.09 | 2019-2025 | Darzalex, Tecvayli, Rybrevant |
| Merck Sharp & Dohme LLC | $535.61 | 2019-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $491.32 | 2019-2025 | Opdivo, Opdualag |
| Celgene Corporation | $368.31 | 2019-2025 | Pomalyst, Reblozyl, Opdualag |
| Abbvie INC. | $332.54 | 2021-2025 | |
| Daiichi Sankyo INC. | $303.50 | 2019-2025 | Enhertu, Injectafer |
| Amgen INC. | $277.61 | 2019-2023 | Blincyto, Vectibix, Xgeva |
| Pharmacyclics LLC, An Abbvie Company | $251.09 | 2019-2023 | Imbruvica, Epkinly |
| Pfizer INC. | $250.61 | 2019-2024 | |
| Deciphera Pharmaceuticals INC. | $240.34 | 2021-2025 | Qinlock, Romvimza, Tgct |
| Astrazeneca Pharmaceuticals LP | $237.54 | 2019-2024 | Calquence |
| Myriad Genetic Laboratories, INC. | $189.24 | 2021-2023 | Precisetumor |
| Ipsen Biopharmaceuticals, INC | $185.11 | 2019-2022 | |
| Eisai INC. | $177.77 | 2019-2022 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Piede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.